Skip to Main content Skip to Navigation
Journal articles

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.

Giovanna Poce 1, * Robert H Bates 2 Salvatore Alfonso 1 Martina Cocozza 1 Giulio Cesare Porretta 1 Lluís Ballell 2 Joaquin Rullas 2 Fátima Ortega 2 Alessandro de Logu 3 Emanuela Agus 3 Valentina La Rosa 4 Maria Rosalia Pasca 4 Edda de Rossi 4 Baojie Wae 5 Scott G Franzblau 5 Fabrizio Manetti 6 Maurizio Botta 6 Mariangela Biava 1, *
* Corresponding author
1 Department of Medicinal Chemistry and Technologies
2 DDW - Diseases of the Developing World [Tres Cantos, Madrid]
3 Dipartimento di Scienze della Vita e dell'Ambiente
4 Dipartimento di Biologia e Biotecnologie
5 Institute for Tuberculosis Research
6 Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena
Abstract : 1,5-Diphenyl pyrroles were previously identified as a class of compounds endowed with high in vitro efficacy against M. tuberculosis. To improve the physical chemical properties and drug-like parameters of this class of compounds, a medicinal chemistry effort was undertaken. By selecting the optimal substitution patterns for the phenyl rings at N1 and C5 and by replacing the thiomorpholine moiety with a morpholine one, a new series of compounds was produced. The replacement of the sulfur with oxygen gave compounds with lower lipophilicity and improved in vitro microsomal stability. Moreover, since the parent compound of this family has been shown to target MmpL3, mycobacterial mutants resistant to two compounds have been isolated and characterized by sequencing the mmpL3 gene; all the mutants showed point mutations in this gene. The best compound identified to date was progressed to dose-response studies in an acute murine TB infection model. The resulting ED(99) of 49 mg/Kg is within the range of commonly employed tuberculosis drugs, demonstrating the potential of this chemical series. The in vitro and in vivo target validation evidence presented here adds further weight to MmpL3 as a druggable target of interest for anti-tubercular drug discovery.
Document type :
Journal articles
Complete list of metadata

Cited literature [18 references]  Display  Hide  Download
https://hal-riip.archives-ouvertes.fr/pasteur-01054300
Contributor : Istituto Pasteur Fondazione Cenci Bolognetti Connect in order to contact the contributor
Submitted on : Tuesday, August 5, 2014 - 7:28:47 PM
Last modification on : Wednesday, November 3, 2021 - 2:18:09 PM
Long-term archiving on: : Tuesday, April 11, 2017 - 7:10:13 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

RIIP | RIIP_FCB

Citation

Giovanna Poce, Robert H Bates, Salvatore Alfonso, Martina Cocozza, Giulio Cesare Porretta, et al.. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.. PLoS ONE, Public Library of Science, 2013, 8 (2), pp.e56980. ⟨10.1371/journal.pone.0056980⟩. ⟨pasteur-01054300⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Les métriques sont temporairement indisponibles